Shangdong Tumour Hospital, Jinan, China.
Biomarkers. 2009 Nov;14(7):480-5. doi: 10.3109/13547500903180265.
Chemoradiotherapy (CRT) is currently performed for patients with advanced esophageal carcinoma. Sensitivity of tumours to CRT differs from one case to another and may be influenced by the expression of biological molecules. The aim of this study was to identify biological markers which could predict sensitivities of esophageal squamous cell carcinoma (ESCC) to CRT.
A total of 84 patients with stage I-IV ESCC were evaluated. The cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) and carcinoembryonic antigen (CEA) levels were measured before CRT by enzyme-linked immunosorbent assays in patients with primary ESCCs using 3.4 ng ml(-1) and 3.3 ng ml(-1), respectively, as cut-off values. The relationships between pretreatment expression of CYFRA 21-1 and CEA and the effectiveness of CRT were analysed.
The complete response (CR) rates of the primary tumours estimated by computed tomography in patients with high levels of CYFRA21-1 and CEA were 10% (3/30) and 4.2% (1/24), while in cases with low CYFRA21-1 and CEA the CR rates were 50% (27/54) and 48.3% (29/60), respectively (p = 0.002 and 0.003). The effective rates (CR+PR) in CYFRA21-1 high and low groups were 60% (18/30) and 96.3% (52/54), while in CEA high and low groups they were 58.3% (14/24) and 93.3% (56/60), respectively (p = 0.013 and 0.013).
CYFRA21-1 and CEA may be helpful in predicting the responsiveness in ESCC of primary lesions to CRT, although the results should be confirmed in larger, more homogeneous studies.
目前对晚期食管癌患者采用放化疗（CRT）。肿瘤对 CRT 的敏感性因人而异，可能受生物分子表达的影响。本研究旨在确定可预测食管鳞状细胞癌（ESCC）对 CRT 敏感性的生物标志物。
共评估 84 例 I-IV 期 ESCC 患者。采用酶联免疫吸附法（ELISA）检测原发性 ESCC 患者的细胞角蛋白 19 片段抗原 21-1（CYFRA21-1）和癌胚抗原（CEA）水平，分别以 3.4ng/ml 和 3.3ng/ml 作为 cutoff 值。分析预处理时 CYFRA 21-1 和 CEA 的表达与 CRT 有效性之间的关系。
根据 CT 估计的原发肿瘤完全缓解（CR）率在高水平 CYFRA21-1 和 CEA 的患者中分别为 10%（30 例中的 3 例）和 4.2%（24 例中的 1 例），而在低水平 CYFRA21-1 和 CEA 的患者中，CR 率分别为 50%（54 例中的 27 例）和 48.3%（60 例中的 29 例）（p=0.002 和 0.003）。CYFRA21-1 高水平和低水平组的有效率（CR+PR）分别为 60%（30 例中的 18 例）和 96.3%（54 例中的 52 例），CEA 高水平和低水平组分别为 58.3%（24 例中的 14 例）和 93.3%（60 例中的 56 例）（p=0.013 和 0.013）。
CYFRA21-1 和 CEA 可能有助于预测原发性病变对 CRT 的反应性，尽管需要在更大、更同质的研究中证实这些结果。
